1204313-58-5

Usage

Uses

Used in Organic Chemistry:
4-chloro-7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalene is used as a synthetic intermediate for the development of new organic compounds. Its unique structure allows for various chemical reactions, enabling the synthesis of novel molecules with potential applications in different industries.
Used in Pharmaceutical Industry:
4-chloro-7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalene is used as a potential drug candidate due to its complex molecular structure. The presence of chlorine, oxygen, and nitrogen atoms in its structure may contribute to its biological activity, making it a promising candidate for the development of new pharmaceuticals.
Used in Materials Science:
4-chloro-7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalene is used as a building block for the development of new materials with unique properties. Its cyclic structure and the presence of various functional groups make it suitable for the creation of advanced materials with potential applications in various industries, such as electronics, coatings, and adhesives.

Upstream product

• 19249-03-7 triethylene glycol di-(p-toluenesulfonate) 

Downstream Products

• 610798-31-7 N-(3-ethynylphenyl)-7,8,10,11,13,14-hexahydro-[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-amine 
• 1355620-29-9 2-(4-fluoro-phenylamino)-5-[5-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-pyridin-2-yl]-3-methyl-3H-pyrimidin-4-one 
• 1355620-21-1 5-(4-fluoro-phenyl)-4-oxo-1,4-dihydro-pyridine-3-carboxylic acid [3-fluoro-4-(7,8,10,11,13,14-hexahydro-6,9,12,15-tetraoxa-1,3-diaza-cyclododeca[b]naphthalen-4-yloxy)-phenyl]-amide 
• 1355620-85-7 3-fluoro-4-[(7,8,10,11,13,14-hexahydro[1,4,7,10]tetraoxacyclododecino[2,3-g]quinazolin-4-yl)oxy]aniline 

Relevant academic research and scientific papers

Preparation method of icotinib key intermediate

The invention discloses a preparation method of an icotinib key intermediate, and belongs to the technical field of drug synthesis. According to the preparation method, triethylene glycol(p-toluene sulfonate) and N-Boc-3,4-dihydroxyl aniline are used as raw materials; the raw materials carry out crown ether cyclization reaction, halogenation reaction and amination reaction (amidation reaction), quinoline cyclization reaction, and chlorination reaction to obtain an icotinib key intermediate, namely 4-chloro-quinazoline[6.7-6]-12-crown-4; the newly designed synthesis route does not need a strongacid solution, which is required by a conventional synthesis route; the dangerous operation is avoided, the generation of a large amount of acidic waste liquid is avoided; and the novel synthesis route has the advantages of simple operation and high yield.

Crown ether cyclic quinazoline compound, preparation method therefor and application thereof in preparing tumor therapy and imaging drug

The invention relates to a crown ether cyclic quinazoline derivative and medicinal salts thereof using in tumor therapy and imaging. The crown ether cyclic quinazoline compound is characterized in that a 2-, 3-, 4- substituted aniline is disposed at one end; a 6-, 7- substituted crown ether cyclic quinazoline structure is disposed at the other end; the substituent group R1 is located on the fourth-position aniline of a quinazoline mother ring and is 2-, 3-, 4- substituted alkoxy; and the crown ether cycle is located at the 6, 7 position of the mother ring, and is a 9-crown-3, 12-crown-4 and 15-crown-5, and the structural formula is formula I. The experimental result of antitumor activity in vitro of nonradioactive isotope labeling compounds shows that the compounds are good in inhibitory effect for four kind of cancer cells namely HepG2, A549, sy5y and DU145, and have the potential as cancer treatment medicine; and the body distribution experiment of 18F or 125I labeling compounds show that the compounds are higher in ingestion and certain detention in tumors and faster in blood clearance and have potential applied to tumor imaging.

Icotinib hydrochloride, synthesis, crystalline forms, pharmaceutical compositions, and uses thereof

The invention relates to 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, its therapeutic usage for treatment of diseases mediated by EGFR kinase and its combinatory therapeutic usage together with other therapeutic agents. The invention also provides synthetic methods for preparation of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride, its new crystalline forms, and the relevant synthetic intermediates for synthesis of 4-[(3-ethynylphenyl)amino]-6,7-benzo-12-crown-quinazoline hydrochloride.

HYDROCHLORIC ACID ICOTINIB, COMPOSITE, CRYSTALLOGRAPHIC FORM, COMBINED MEDICINE AND ITS APPLICATION

PROBLEM TO BE SOLVED: To provide a production method of a medicine which is an epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, for treating and preventing excessive non-malignancy hyperplasia, pancreatitis, renal disease, cancer, arterialization or an angiogenesis-related disease of a mammal, or a medicine for germ cell transplantation of a mammal. SOLUTION: There is provided a use of 4-[(3-ethynyl phenyl)amino]-6-7-benzo-12-crown-hydrochloric acid quinazoline, illustrated by following formula, and these novel crystals (I, II, III, IV) for treatment of EGFR kinase-intermediating pathogen, and a use for treatment by joint use with another therapeutic agent. COPYRIGHT: (C)2015,JPO&INPIT